The Public Sector Contracting Platform has published the awarding to the company “Depur GM Deseño e Obra S.L” to carry out the improvement works in the CCMIJU’s Animal Housing within the framework of the project “Updating the Infrastructures and implementation of a LIMS document control and management system to enhance the capacities of the Distributed ICTS NANBIOSIS Units managed by the CCMIJU (AILIMS-NANBIOSIS).
For further details, please click here
The mentioned project has been co-funded by the European Regional Development Fund (FEDER) through the Ministry of Science and Innovation within the framework of the Programa Operativo Plurirregional de España (POPE) for Singular Scientific and Technical Infrastructures (ICTS) 2014-2020 and by the Consejería de Economía, Ciencia y Agenda Digital of Junta de Extremadura.
The following actions are considered in the framework of the project:
-Within Unit 22 or Animal Facility, the Installation and development of an environmental treatment-control system of the housing rooms, an Improvement and adaptation of the spaces for experimental models, the Acquisition, installation and development of a two-door ultra- filtered air shower and the Acquisition, installation and development of a post-procedural recovery chamber.
– For the rest of the NANBIOSIS Units managed by the CCMIJU: Acquisition, installation and development of a LIMS Software.
The actions and their budget are detailed below, together with the FEDER co-funded rate and the national contribution.
The Scientific Commission of ‘La Marató TV3’ has seleced the project entitled “Diagnosis and treatment of Sars-Cov-2 by triplex formation”, led by Ramon Eritja, Scientific Director of NANBIOSIS Unit 29 Oligonucleotide Synthesis Platform (OSP) from CIBER-BBN and IQAC_CSIC to be financed with € 398,750.00. Verónica Noé from the Fundació Bosch i Gimpera Universitat de Barcelona, the CIBERESP researcher Enrique Calderón Sandubete, from the Virgen del Rocío University Hospital and María Valeria Grazú Bonavía, from the Institute of Nanoscience and Materials of Aragón, INMA (CSIC- UNIZE) also participate in this project.
The edition of this solidarity initiative promoted by the Corporació Catalana de Mitjans Audiovisuals, raised more than twelve million euros to finance research against COVID-19. The project was selected, among the 229 submitted, to receive funding for its development.
“Our project wants to solve two important problems in the fight against the COVID-19 pandemic: the first is how to quickly and specifically detect people infected by this virus; and the second is that right now we do not have a effective therapy specifically designed to be used against the virus that causes COVID-19 “explains Dr. Eritja.
The project will try to solve both problems using synthetic oligonucleotides with high and specific affinity for viral RNA. “In recent years, a dozen oligonucleotides have been approved by Health agencies (EMA and FDA) for the treatment of genetic diseases such as Duchene muscular dystrophy as well as metabolic diseases such as familial hypercholesterolemia. In the project we will use specific oligonucleotides, procuced at NANBIOSIS U29, to bind viral RNA that could be used in vitro for the selective capture and diagnosis of the SARS-.COV-2 virus, but also in vivo to inhibit the replication of viral RNA “adds Ramón Eritja.
The call for grants from ‘La Marató’ was carried out, exceptionally, between the months of December and January. Until May, the 229 candidate projects have been reviewed electronically, following a process of proven rigor and transparency, coordinated by the Catalan Agency for Quality and Health Evaluation, in which 95 international evaluators have participated. The assessment, among other aspects, of the quality, the methodology, the scientific, health and social relevance, the innovative value and the viability of the candidate works has determined which projects have been financed with the resources of La Marató 2020.
With this new edition from La Marató, the solidarity project of the Catalan Audiovisual Media Corporation and the Foundation since 1992 an amount of € 216 million have been awarded and a total of 949 research projects hve been promoted, with participation of 9,350 researchers have participated.
The management of musculoskeletal pain is a key challenge due to the short duration of anesthetic effect produced by existing clinical treatments, in addition to their potential side effects. Researchers from the CIBER-BBN, the Institute of Nanoscience and Materials of Aragón (INMA), CSIC-University of Zaragoza and the Institute of Health Research of Aragón (IIS Aragón), in collaboration with researchers from the Faculty of Veterinary Medicine of the University of Zaragoza and with participation of NANBIOSIS Unit 9 Synthesis of Nanoparticles Unit, have developed nanogels loaded with nanocrystals of bupivacaine (an anesthetic commonly used in epidural anesthesia and in the control of postoperative pain) obtaining a high drug content for a prolonged duration of local anesthesia.
These nanogels are an alternative to the most prescribed analgesics (antipyretics, steroids and opioids), which frequently present adverse effects such as nausea, vomiting, dizziness and physical dependence, among others. They consist of a biocompatible polymer derived from polyethylene glycol (PEG) that has heat-sensitive properties, so that they would be injected at room temperature and upon reaching body temperature after administration they undergo a change in their structure, resulting in a reduction in their volume. and transforming into a hydrophobic structure, thus controlling the release of the drug encapsulated within.
According to Manuel Arruebo, INMA-CIBER-BBN researcher, “we have validated this new way of dispensing the local anesthetic both in cell cultures and in animal experiments, showing that it increases the duration of sciatic nerve block twice compared to the same dose of free anesthetic. The synthesis of the drug nanocrystals has been carried out in NANBIOSIS U9 (from CIBER-BBN and University of Zaragoza) thanks to the wet chemical synthesis systems of the platform“.
The prolonged duration of anesthetic action can be explained by the regional immobilization of the nanogels at the injection site around the sciatic nerve due to their hydrophobic nature, preventing the diffusion of drug particles and their rapid elimination while interacting efficiently with the tissues thanks to to its temperature-induced conformational change. Studies have shown that this delivery system has low toxicity and does not give rise to an inflammatory response due to the slow release of the drug and the high biocompatibility of the polymer used.
The encapsulation of drug nanocrystals is a promising strategy, which allows reducing the total amount of drug necessary to produce pain relief with the consequent benefits obtained from the reduction of toxicity.
For their part, the researchers Teresa Alejo (INMA) and Víctor Sebastián (CIBER-BBN-INMA) affirm that “through these systems we seek to obtain an effective vehicle capable of prolonging the anesthetic effect in its place of action, avoiding as far as possible the side effects. In this way, they could be used to avoid systemic administration, reduce high concentrations in the blood and reduce the unwanted side effects of some conventional treatments, since they allow to control the release of the drug within the desired therapeutic range, avoiding the consequences of an excess of drug and the negative effects that this implies ”.
Likewise, with this technique the satisfaction and comfort of the patient is considered, since with a single dosage a prolonged therapeutic effect would be achieved. In Europe, with more than 500 million days of sick leave per year, musculoskeletal pain causes almost 50% of all absences from work lasting at least three days and 60% of permanent absences from work. Consequently, pain has a huge impact on work productivity. Some data indicate that the annual cost of pain is greater than the cost of heart disease, cancer and diabetes.
Therefore, the development of an effective injectable local anesthetic with a prolonged duration of action can improve the quality of life of patients affected by these diseases.
Article of refernce:
Teresa Alejo, Laura Usón, Guillermo Landa, Martin Prieto, Cristina Yus Argón, Sara García-Salinas, Ricardo de Miguel, Ana Rodríguez-Largo, Silvia Irusta, Victor Sebastián, Gracia Mendoza and Manuel Arruebo. Nanogels with High Loading of Anesthetic Nanocrystals for Extended Duration of Sciatic Nerve Block, ACS Appl. Mater. Interfaces, 13, 15, 17220–17235. 2021 April 6. [DOI]
Parkinson’s disease (PD) is a common neurodegenerative disorder caused by the death of dopaminergic neurons in a part of the brain (known as substantia nigra pars compacta), which leads to a deficit of dopamine (DA), one of the main neurotransmitters active in the central nervous system. Symptomatic treatment focuses on increasing the concentration of dopamine into the brain.
However, dopamine is not directly administered, because it is unable to cross the so called blood-brain barrier, which prevents some of the substances circulating in the blood to penetrate into the nervous system. Thus, DA precursor levodopa (L-DOPA) –an amino-acid which participates in the synthesis of dopamine– is used, due to its better ability to cross such barrier. Nevertheless, long-term and intermittent administration of this drug is associated with important disabling complications, such as motor disorders and involuntary muscle movements.
In a paper recently published in ACS Nano, synthetic melanin-like nanoparticles are used to overcome these limitations. This research was coordinated by Dr Daniel Ruiz-Molina, leader of the ICN2 Nanostructured Functional Materials Group, and Dr Julia Lorenzo, leader of the Protein Engineering Group at the Institute of Biotehcnology and Biomedicine (IBB) of the Universitat Autònoma de Barcelona (UAB), and was developed in collaboration with the Neurodegenerative Diseases group of Vall d’Hebron Research Institute (VHIR), led by Prof. Miquel Vila.
The main objective of this work was to obtain a “nanoplatform” –which is a biocompatible nano-structure including the substance to be delivered– able to reach the brain through a noninvasive route and generate a slow and controlled release of dopamine. A tailor-made nanoscale coordination polymer (NCP), characterized by the reversible incorporation of DA as its principal component, was tested in vitro and in vivo in rats. Intranasal administration of these nanoparticles, called DA-NCPs, showed a relevant biocompatibility, non-toxicity and a fast and efficient distribution of dopamine in the central nervous system of the animals (avoiding the blood-brain barrier).
Ex vivo and in vivo preclinical MRI acquisitions were performed at U25 of NANBIOSIS ICTS NMR: Biomedical Applications I
As reported by the researchers, the proposed method is effective in delivering dopamine to the brain and, thus, in reversing Parkinson’s symptoms. In addition, the synthetic methodology used is simple, cheap and exhibited a satisfactory yield (with a DA loading efficiency up to 60%).
These findings establish nanoscale coordination polymers as promising future candidates for efficient nasal delivery of drugs to the central nervous system, and thus for the symptomatic treatment of people affected by Parkinson’s and other neurodegenerative disorders. This type of nano-formulation and administration route may also pave the way to the development of other platforms able to deliver a wide range of drugs into the brain in a controlled manner, for the treatment of various brain diseases (such as brain tumours, Alzheimer’s, Epilepsy).
Javier García-Pardo, Fernando Novio, Fabiana Nador, Ivana Cavaliere, Salvio Suárez-García, Silvia Lope-Piedrafita, Ana Paula Candiota, Jordi Romero-Gimenez, Beatriz Rodríguez-Galván, Jordi Bové, Miquel Vila, Julia Lorenzo, and Daniel Ruiz-Molina, Bioinspired Theranostic Coordination Polymer Nanoparticles for Intranasal Dopamine Replacement in Parkinson’s Disease. ACS Nano 2021, 15, 5, 8592–8609, May 2021. [DOI]
The Ministry of Science and Innovation has approved a call for ICTS for 37 million euros.
Investment lines of the ICTS associated with the construction, development, instrumentation, equipment and improvement of scientific-technical capacities of the ICTS will be financed with the 100% of the eligible cost.
This call is funded by the European Union Recovery and Resilience Mechanism.
The Singular Scientific and Technical Infrastructures (ICTS) are large, one-of-a-kind facilities, which are dedicated to cutting-edge technological research and development of the highest quality, as well as promoting the transmission, exchange and preservation of knowledge, technology transfer and innovation. They are distributed throughout the territory and included in the ICTS Map.
The aim of this call is the execution of investments included in the Strategic Plans of ICTS that have been declared of high priority by the Advisory Committee of Singular Infrastructures (CAIS) within the framework of the update of the ICTS Map 2017-2020. The total eligible cost of each application must be between 100,000 euros and 10 million euros.
In 2022 another call will be published for 37 million euros to finance actions of the new strategic plans of the ICTS 2021-2024.
The deadline for submitting applications will be from June 2 to June 22, 2021 at 2:00 p.m.